#今日行業(yè)熱點(diǎn)#

?

①The New England Journal of Medicine：Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

NEJM首次發(fā)表中國(guó)創(chuàng)新藥試驗(yàn)——澤布替尼和伊布替尼治療復(fù)發(fā)或難治性慢性淋巴細(xì)胞白血病的比較

DOI: 10.1056/NEJMoa2211582

②Nature Reviews Immunology：The role of platelets in immune-mediated inflammatory diseases

血小板在免疫介導(dǎo)的炎癥性疾?。↖MIDs）中的作用

DOI :10.1038/s41577-023-00834-4

③Arthritis & Rheumatology：Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist that Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases

增強(qiáng)型雙APRIL/BAFF拮抗劑Povetacicept可調(diào)節(jié)B淋巴細(xì)胞和致病性自身抗體，用于治療狼瘡和其他B細(xì)胞相關(guān)自身免疫疾病

DOI :10.1002/art.42462

④Science：Low protease activity in B cell follicles promotes retention of intact antigens after immunization

B細(xì)胞濾泡的低蛋白酶活性促進(jìn)免疫后完整抗原的保留

DOI :10.1126/science.abn8934

⑤Cell Metabolism：Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates

活性平衡的GLP-1/GDF15雙激動(dòng)劑降低小鼠和非人類靈長(zhǎng)類動(dòng)物的體重和代謝障礙

DOI :10.1016/j.cmet.2023.01.001

⑥Allergy：Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice

人源單克隆抗體靶向Ara h 2預(yù)防花生誘導(dǎo)的小鼠過敏反應(yīng)

DOI :10.1111/all.15659

⑦首個(gè)針對(duì)BTK抗性癌癥——禮來非共價(jià)選擇性布魯頓氏激酶（BTK）抑制劑獲FDA加速批準(zhǔn)

⑧歌禮制藥宣布口服病毒聚合酶抑制劑ASC10猴痘適應(yīng)癥新藥臨床試驗(yàn)申請(qǐng)獲得中國(guó)國(guó)家藥監(jiān)局批準(zhǔn)

⑨對(duì)美國(guó)主流變異株無效！阿斯利康新冠中和抗體緊急使用授權(quán)被FDA撤回

⑩靶向B細(xì)胞成熟抗原（BCMA）的CAR-T療法Carvykti可顯著改善復(fù)發(fā)/難治性多發(fā)性骨髓瘤（RRMM）成人患者的無進(jìn)展生存期（PFS）

?

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！